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Abstract
Background: The DLX gene family encodes for homeobox transcription factors involved in the control of
morphogenesis and tissue homeostasis. Their expression can be regulated by Endothelin1 (ET1), a peptide associated
with breast cancer invasive phenotype. Deregulation of DLX gene expression was found in human solid tumors and
hematologic malignancies. In particular, DLX4 overexpression represents a possible prognostic marker in ovarian
cancer. We have investigated the role of DLX genes in human breast cancer progression.
Methods: MDA-MB-231 human breast carcinoma cells were grown in vitro or injected in nude mice, either
subcutaneously, to mimic primary tumor growth, or intravenously, to mimic metastatic spreading. Expression of
DLX2, DLX5 and DLX6 was assessed in cultured cells, either treated or not with ET1, tumors and metastases by RT-
PCR. In situ hybridization was used to confirm DLX gene expression in primary tumors and in lung and bone
metastases. The expression of DLX2 and DLX5 was evaluated in 408 primary human breast cancers examining the
GSE1456 and GSE3494 microarray datasets. Kaplan-Meier estimates for disease-free survival were calculated for the
patients grouped on the basis of DLX2/DLX5 expression.
Results: Before injection, or after subcutaneous growth, MDA-MB-231 cells expressed DLX2 but neither DLX5 nor
DLX6. Instead, in bone and lung metastases resulting from intravenous injection we detected expression of DLX5/6
but not of DLX2, suggesting that DLX5/6 are activated during metastasis formation, and that their expression is
alternative to that of DLX2. The in vitro treatment of MDA-MB-231 cells with ET1, resulted in switch from DLX2 to
DLX5 expression. By data mining in microarray datasets we found that expression of DLX2 occurred in 21.6% of
patients, and was significantly correlated with prolonged disease-free survival and reduced incidence of relapse.
Instead, DLX5 was expressed in a small subset of cases, 2.2% of total, displaying reduced disease-free survival and
high incidence of relapse which was, however, non-significantly different from the other groups due to the small size
of the DLX+ cohort. In all cases, we found mutually exclusive expression of DLX2 and DLX5.
Conclusions: Our studies indicate that DLX genes are involved in human breast cancer progression, and that DLX2
and DLX5 genes might serve as prognostic markers.
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The abnormal expression of homeobox genes in many
solid tumors and hematological malignancies [1,2] has
reinforced the notion that these key regulators of embryo-
genesis can also play a role in neoplastic processes. DLX
genes, the vertebrate homologues of Drosophila distal-less
(dll), constitute a family of homeobox transcription factors
involved in control of cell differentiation and morphogen-
esis. The mouse and human DLX gene system is formed
by three bi-gene clusters: DLX1a n dDLX2; DLX5a n d
DLX6; DLX3a n dDLX4. All DLX genes are expressed by
embryonic stem cells and play a role in the control of cra-
niofacial embryogenesis [3], of neurogenesis [4], and of
formation of the distal regions of extending appendages
[5]. Furthermore, DLX5 and DLX6 are expressed in all
developing bones and control osteoblastogenesis and
osteoblast/osteoclast coupling Although DLX genes are
expressed in several adult tissues, including bone, brain
and epithelia, little is known about their possible involve-
ment in neoplastic process. We have previously demon-
strated [6,7] that Dlx genes participate to the regulatory
cascade initiated by acute lymphoblastic leukemia (ALL)-1
gene, a master regulator gene whose disruption is impli-
cated in human acute leukemias [8]. DLX genes respond
differently to the t(4;11)(q21;q23) chromosomal abnormal-
ity: while the expression of DLX2, DLX3, and DLX4 is vir-
tually abrogated, that of DLX5 and DLX6 is increased [8].
These data indicate that different members of the DLX
gene family could play diverse roles in predisposing cells
to leukemic transformation. Furthermore, evidences have
been found on DLX5 involvement in T-cell lymphomas
both in mouse models and in humans [9].
In non-hematological malignancies most of the avail-
able information concerns DLX4. DLX4 overexpression
by ovarian cancer is strongly associated with high tumor
grade and advanced disease stage [10]. This gene, when
overexpressed in the breast cancer cell line MCF7, inhi-
bits apoptosis [11]. However, recently published micro-
array studies demonstrated the upregulation of DLX5 in
several human solid tumors, suggesting that overexpres-
sion of DLX5 could contribute to tumor progression
and represent a novel prognostic marker [12,13]. The
analysis of factors involved in Dlx gene regulation has
evidenced that Endothelin1 (ET1)i sd i r e c t l yi n v o l v e di n
the activation of Dlx5 and Dlx6 and inhibits the expres-
sion of Dlx2 [14-16]. It is of note that ET1 expression
has been directly associated to the invasive phenotype of
breast tumor cells [17].
Methods
2.1. Cell culture and ET1 treatment
MDA-MB-231 cells were obtained from Dr. Paola Man-
duca (Dipartimento di Oncologia, Biologia e Genetica,
Università di Genova, Italy). Cells were grown in
DMEM supplemented with 10% Fetal Calf Serum (FCS),
1% glutamine and 1% penicillin/streptomycin (all from
Biochrom Seromed, Berlin, Germany) at 37°C in 5%
CO2 atmosphere.
For ET1 treatment, adherent sub-confluent MDA-MB-
231 cells were starved for 24 h in serum-free medium,
trypsinized and centrifuged. Pellets were resuspended in
serum-free medium either containing or not 100 nM
ET1 (Sigma Aldrich, St. Louis, MO); cells were then pla-
ted into a 12-well tissue culture plate and incubated for
8 h. Total RNA was then isolated from each well using
the RNeasy kit (QIAGEN, Hilden, Germany), according
to manufacturer’s instructions. All experiments were
run in triplicate.
2.2. Animals
We used nude female mice of 5-6 weeks of age (Charles
River, Calco, Italy) housed in laminar flow isolated
hoods at the Animal Facility of the National Institute
for Cancer Research in Genova. Housing and treatments
of animals were in accordance with the Italian and Eur-
opean Community guidelines (D.L. 2711/92 No.116; 86/
609/EEC Directive), and approved by the internal Ethic
Committee.
2.3. Injection of MDA-MB-231 in mice
Sub-confluent MDA-MB-231 cells were trypsinized, resus-
pended in PBS and counted. Primary tumors were
obtained by injecting 3 nude mice subcutaneously with
4×1 0
6 MDA-MB-231 cells. Nodules developed within
2-3 weeks and were dissected when they reached an
approximate volume of 250 mm
3, generally within 1
month from injection. Metastases were obtained by injec-
tion of 2 × 10
5 cells in 100 μl of PBS in the left cardiac
ventricle of 10 nude mice. Mice were sacrificed 2 months
after cell inoculation and subjected to necropsy. Before
sacrifice bone metastases were identified by radiography.
Nodules and metastases were immediately processed for
total RNA extraction or paraffin embedding.
2.4. Human samples
We examined normal breast tissues from 2 women under-
going reductive mammoplastic and primary breast cancer
tissues from 2 patients undergoing curative surgery, one
for invasive ductal carcinoma and one for invasive mixed
carcinoma. Samples were kindly provided by Dr. L. Mas-
tracci (Dipartimento di Discipline Chirurgiche, Anestesio-
logiche, Morfologiche e Metodologie Integrate, Università
di Genova, Italy), through the GTB (Genoa Tissue Bank).
Written informed consent was obtained from all patients
and approved by the S. Martino Hospital’s Ethical Com-
mittee, Genova, Italy. This investigation conformed the
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and DLX5 expression was investigated by RT-PCR.
2.5. Immunohistochemistry
All bones (hindlimbs, ribs and tail) were fixed overnight
in 4% paraformaldehyde (PAF) at 4°C, washed in PBS,
decalcified for 18-24 hrs inO s t e o d e c( B i o - O p t i c a ,
Milano, Italy) and embedded in paraffin. All other
organs were fixed in 4% PAF at 4°C, washed in PBS and
embedded in paraffin. For immunohistochemistry stain-
ing, de-waxed sections were treated in microwave oven
for 15 min in 10 mM citrate buffer pH 6.0 and incu-
bated with 3% H2O2 for 10 min. After 1 hr in blocking
solution (10% normal goat serum in PBS), sections were
incubated for 40 min at room temperature with either a
rabbit monoclonal anti-Ki67 (1:250) or a mouse mono-
clonal anti-Keratin 18 (K18) Ab-8 clone L2A1 (1:100)
(NeoMarkers, Fremont, CA). After washing with PBS,
sections were incubated with the appropriate secondary
biotinylated antibody (BIO-SPA, Milano, Italy) for 30
min at room temperature followed by 10 min incubation
with horseradish peroxidase (HRP)-conjugated streptavi-
din (BIO-SPA). HRP enzymatic activity was then
revealed with diaminobenzidine (DAB).
2.6. In situ hybridization
8 μm sections were de-waxed, rehydrated, incubated in
10 μg/ml Proteinase K for 20 min at 37°C, and fixed
with 4% PAF for 15 min at room temperature (RT).
After washing in PBS, slides were incubated for 10 min
in 0.2 M triethanolamine and 0.25% acetic anhydride,
washed with PBS and incubated 15 min in PBS contain-
ing 1% Triton X-100. After washing, sections were pre-
hybridized in 50% formamide, 5× SSC, 5X Denhardt’s
solution, 0.25 mg/ml yeast tRNA, 0.5 mg/ml salmon
sperm DNA (all from Sigma). Overnight hybridization
was performed at 60°C in prehybridization buffer con-
taining 0.5 μg/ml probe. Dlx5 and Dlx6 probes were
kindly provided by Dr. Giorgio Merlo (Università di
Torino, Italy). Slides were washed in 5X SSC 5 min at
60°C, 1 hr at 60°C with 0.2 XSSC, 5 min in 0.2X SSC at
RT and then incubated for 1 hr with blocking solution
containing 10% goat serum in 0.1 M Tris pH 7.5,
0.15 M NaCl at RT in a humidified chamber. Alkaline
Phosphatase-conjugated anti-digoxigenin antibody
(Roche Biochemicals, Basel, Switzerland) in blocking
solution was then added to slides and incubated over-
night at 4°C in a humidified chamber. Finally slides
were washed in a solution containing 0.1 M Tris pH 7.5,
0.15 M NaCl, equilibrated 5 min in a solution contain-
ing 0.1% Tween 20, 0.1 M Tris pH 9.5, 0.1 M NaCl,
0.05 M MgCl2, 1 mM levamisole and stained with
BMPurple (Roche). Negative controls were run in paral-
lel using sense probes.
2.7. RT-PCR
T o t a lR N Aw a si s o l a t e df r o m7 0 - 8 0 %c o n f l u e n tM D A -
MB-231 cells and from human and murine tissue sam-
ples using the RNeasy mini kit (QIAGEN). Reverse
transcription of 1 μg of DNase I-treated total RNA was
performed using a Mo-MLV RNase-H(-) RT (Promega,
Madison, WI) in a reaction volume of 20 μl. Resulting
cDNA was then diluted by addition of 30 μlo fw a t e rt o
reach a final volume of 50 μl and a concentration of
cDNA 10×. Two μl of cDNA were used for amplifica-
tion using TaqDNA polymerase (TibMolBiol, Genova,
Italy).
The following primers were used:
human DLX5 sense 5’-ACCATCCGTCTCAGGAATCG
human DLX5 antisense 5’-ACCTTCTCTGTAATG
CGGCC
human DLX6 sense 5’-GAACTGGCAGCTTCCTTA
human DLX6 antisense 5’-ACCAGTGAGAATA
GCCAG
human DLX2 sense 5’-CTCTGCCTGCCTCAT
AAGG
human DLX2 antisense 5’-ATCGTAAGAACAGCG
CAACC
human G3PDH sense 5’-GAAGGTGAAGGTCG
GAGT
human G3PDH antisense 5’-TGGTTTCCGGACTTT
CTTTG
murine b-actin sense 5’-TCGTGGGCCGCTCTA
GGCAC
murine b-actin antisense 5’-TGGCCTTAGGGTTCA
GGGGG.
The primers used for RT-PCR where specific for the
human DLX genes and did not recognize mouse Dlxs.
Annealing temperature was set to 60°C in all case, using
25 cycles for G3PDH and b-actin, and 35 cycles for the
other genes.
2.8. Microarray data analysis
Expression analyses of human breast cancers were per-
formed on the dataset GSE1456 [17] and GSE3494 [18]
obtained from Gene Expression Omnibus http://www.
ncbi.nlm.nih.gov/geo. The data sets consists of 159 and
249 breast cancers from unselected consecutive patients
who received surgery at Karolinska Hospital from
1994-1996 or at the Uppsala County Hospital from
1987-1989, respectively. Expression sets were calculated
from raw microarray of the two combined datasets
using the GCRMA algorithms implemented in Biocon-
ductor [19]. The threshold level of positive gene expres-
sion was set to five on the log2-scale [20]. GeneSpring
7.1 (Agilent, Santa Clara, CA) software was used for
visualization of expression data. Samples were clustered
according to the expression of DLX2 and DLX5 to
enhance visual interpretation by hierarchical clustering
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free survival were calculated using the package “survival”
of Bioconductor [19].
Results
3.1. DLX5, DLX6 and DLX2 expression in MDA-MB-231
cells, primary tumors and metastasis
To analyze the role of DLX2, DLX5, and DLX6 in breast
primary tumor and metastasis formation, we used an
experimental model of breast cancer metastasis. The
MDA-MB-231 human mammary carcinoma cell line
gives rise to metastases in several organs, including
bones, when inoculated into the left cardiac ventricle of
immunocompromised mice [21]. Instead, when MDA-
MB-231 cells are injected subcutaneously, a nodule
grows at the site of injection, without significant meta-
static spreading [22]. We first analyzed the expression of
DLX genes by RT-PCR in MDA-MB-231 cells in sub-
confluent culture, the same cell density used for in vivo
experiments. We found that cells express DLX2,b u t
neither DLX5 nor DLX6 (Figure 1). Then, to assess DLX
gene expression in primary tumors, we injected MDA-
MB-231 cells subcutaneously in nude mice. By RT-PCR
analysis we found that subcutaneous nodules were posi-
tive for DLX2,b u tn e i t h e rf o rDLX5 nor for DLX6,a s
the in vitro cultured cell line (Figure 1). Instead, a differ-
ent expression pattern was found when the expression
of DLX2, DLX5,a n dDLX6 was checked in lung and
bone metastases growing from MDA-MB-231 cells
injected into the left cardiac ventricle. Expression of
DLX5 and DLX6,b u tn o to fDLX2,w a sf o u n db y
RT-PCR in lung metastases, a result opposite to that
o b t a i n e di nc u l t u r e dc e l l sa n d subcutaneous nodules,
suggesting that activation of DLX5/6 and suppression of
DLX2 had taken place during metastasis formation
(Figure 1). To obtain a confirmation, we analyzed by
in situ hybridization the expression of DLX5 and DLX6
on tissue sections of lung and bone metastases. Metas-
tases showed high levels of DLX5 and DLX6 expression
(Figures 2B, C and 3D, E). It is interesting to note that
in situ hybridization on bone metastases showed an
increased DLX5/6 expression signal intensity in tumor
cells in close contact with the bone tissue, suggesting a
correlation between expression of these genes and the
invasion front. DLX5 and DLX6 signals co-localized with
that of human K18, identified by immunohistochemistry
with a human-specific antibody not cross-reacting with
mouse, confirming that DLX-expressing cells were
indeed of human origin (Figure 3G). To assess if DLX5/
6 expression was related to cell proliferation, sections
adjacent to those used for hybridization were stained
with an anti-Ki67 antibody that specifically identifies
actively proliferating cells. We could not find any clear
correlation between the staining obtained with in situ
hybridization and the location of Ki67-positive nuclei
(Figure 3F). Confirming the results obtained by
RT-PCR, no expression of DLX5 or DLX6 was found in
subcutaneous nodules (Figure 3B, C).
3.2. ET1 treatment of MDA-MB-231 cells induces DLX2 to
DLX5 switch
During embryonic development ET1 plays a central role
in the control of Dlx gene expression. In particular ET1
signaling is necessary and sufficient for the activation of
Dlx5 in the mandibular arch [14,16]. ET1 expression has
been directly associated to the invasive phenotype of
breast tumor cells in mouse models, but cultured MDA-
MB-231 cells do not express ET1 [23]. To test whether
ET1 signaling could be at the origin of the switch in
DLX gene expression observed during metastasis forma-
tion, starved MDA-MB-231 cells where treated with
ET1. We observed a clear reduction of DLX2 expression,
paralleled by induction of DLX5 (Figure 4), suggesting
that ET1 signaling could be involved in the DLX2t o
DLX5 switch observed in metastases.
3.3. DLX2 expression in human breast cancer is positively
associated with disease-free survival
In order to assess the role of DLX2 and DLX5 gene
expression also in humans, we performed a preliminary
analysis of the DLX status on 2 samples of normal
breast tissue and on 2 samples of primary breast tumor.
Normal breast tissues expressed DLX2 but not DLX5.
Figure 1 Expression of DLX2, DLX5 and DLX6 in MDA-MB231
cells in vitro and in vivo. The pattern of expression of DLX2, 5 and
6 in cultured MDA-MB-231 cells paralleled that observed in nodules
resulting from subcutaneous injection into nude mice: a strong
DLX2 expression was found, while neither DLX5 nor DLX6 were
present. Lung metastases generated by injection of MDA-MB-231
into the left cardiac ventricle of nude mice displayed the opposite
pattern of expression, with undetectable levels of DLX2 and high
levels of DLX5 and 6.
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positive for DLX5,b u tn e g a t i v ef o rDLX2 (Figure 5A).
These preliminary findings indicate that in humans, as
in mice, expression of DLX5 could be related to meta-
static capacity. To confirm this hypothesis, we analyzed
the expression of DLX genes in a dataset of 408 cases of
human breast cancers obtained from Gene Expression
Omnibus, and correlated results with disease-free survi-
val and relapse. In mammary tumors, the expression
levels of DLX1, DLX3, DLX4 and DLX6 did not signifi-
cantly differ from those observed in normal tissue (data
not shown). Instead, DLX2 was expressed in 21.6%
(88/408) of the tumors, while DLX5 expression was pre-
sent in only 2.2% (9/408) of the tumors (Figure 5B). In
all cases expression of the two genes was mutually
exclusive, in no instance co-expression of DLX2 and
DLX5 was observed. Patients were then divided into
three groups, i.e. DLX2+/DLX5-, DXL2-/DLX5+ and
DLX2-/DLX5-, and disease-free survival and relapse
were assessed. The DLX2+/DLX5- patients had the long-
est average disease-free survival, whilst the DLX2-/DLX5
+ patients had the shortest one. Kaplan-Meier analysis
of disease-free survival showed a significant difference
between the DLX2+/DLX5- and DLX2-/DLX5- groups
(p = 0.018), however, the very small size of the DLX2-/
DLX5+ sample resulted in non-significant difference
when comparing this group of patients with either the
DLX2+/DLX5- or the DLX5/2- groups (Figure 5C and
5D). Taking into account the age of patients as a co-var-
iant did not modify these results.
Discussion
Several homeobox genes are deregulated in a variety
human tumors, and their deregulation appears to
enhance cell survival and proliferation and to inhibit dif-
ferentiation [2]. Among the DLX family of homeobox-
containing genes, BP1,a ni s o f o r mo fDLX4,w a sf o u n d
to correlate with poor prognosis in human breast cancer
[24]. In the present study we specifically investigated the
involvement of DLX2 and DLX5/6 in breast tumor
progression.
In our mouse model, we found that DLX5 and
DLX6, not expressed by MDA-MB-231 cells either
cultured or grown subcutaneously, were specifically
Figure 2 In situ hybridization for DLX5 and DLX6 in MDA-MB-231 bone metastases. (A) A bone metastasis, visualized by radiography. (B
and C) In-situ hybridization on sections of long bones containing MDA-MB-231 metastases showing high expression of DLX5 and DLX6. The
signal was more intense at the invasion front (arrows). bn, cortical bone; met, metastasis.
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the contrary, DLX2 was expressed in cultured cells
and in subcutaneous nodules, but not in bone or lung
metastases. These results indicate that transition to
metastatic phenotype is characterized by inhibition of
DLX2 and induction of DLX5/6 expression. The
expression of DLX5/6 in metastases of different tissues
suggests that this phenomenon is independent from
the microenvironment present at the site of metastasis
formation. The lack of relationship with Ki67 expres-
sion indicates that in this model the expression of
DLX5/6 is independent also from cell proliferation,
though previous data indicated that Dlx5 contributes
to increased cell proliferation in mouse thymic lym-
phomas [9].
Figure 3 In situ hybridization for DLX5 and DLX6 in MDA-MB-231 lung metastases and subcutaneous nodules. (A and C) Expression of
DLX5 and DLX6 analyzed by in situ hybridization on sections of nodules derived by subcutaneous injection of MDA-MB231 cells in nude mice or
(D and E) in sections of lung metastases derived from intracardiac injection of the same cells. (F) The proliferative state of the metastases was
evidenced by Ki67 immunostaining. (G) K18 immunostaining of metastases was used to specifically identify human cells.
Figure 4 ET1 treatment of MDA-MB-231 cells induces DLX2 to
DLX5 switch. Expression of DLX2 and DLX5 expression in of MDA-
MB-231 cells treated with ET1. Subconfluent cultures were serum-
starved and treated with vehicle alone (-) or ET1. RT-PCR analysis for
DLX2, DLX5 and G3PDH was performed on total RNA isolated from
individual wells.
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Page 6 of 9Figure 5 DLX2 and DLX5 expression and correlation with disease-free survival in human breast cancers.( A )DLX2 and DLX5 expression
were analyzed by RT-PCR in normal breast tissue (lane 1), ductal breast carcinoma (lane 2), and mixed breast carcinoma (lane 3). (B) Relative
expression of DLX2 and DLX5 in 408 human breast cancer samples as analyzed by microarrays (Gene Expression Omnibus datasets GSE1459 and
GSE3494). Expression values are color-coded, red: expression above the mean value, green: expression below the mean value. Intensity of colour
correlates to the strength of up- or downregulation. Samples are ordered by hierarchical clustering based on the expression values of these two
genes. Incidence of relapse is indicated in the lower bar (brown: no relapse, pink: relapse; 12 year follow-up). (C) Kaplan-Meier estimates of
disease free survival of DLX2+/DLX5- patients (n = 88), DLX2-/DLX5- patients (n = 311), and DLX2-/DLX5+ patients (n = 9). (D) Statistical analysis of
relapse incidence among the three groups. The incidence of relapse was 18/88 for DLX2+/DLX5- patients, 106/311 for DLX2-/DLX5- patients, and
5/9 for DLX2-/DLX5+ patients. P = p-value, RR = relative risk, OR = odds ratio, CI = confidence interval.
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bition of DLX2 and induction of DLX5 expression in
breast cancer, as compared with normal breast tissue.
Furthermore, analysis of microarray data on human breast
tumors showed that breast cancer patients with DLX2
expression had on average better prognosis and less inci-
dence of relapse, while DLX5 expression and DLX2 down-
regulation, was related to a subset of more aggressive
tumors. In the data set we examined BP1 had not been
studied, so we cannot confirm the previous finding of a
relationship between the expression of this gene and poor
prognosis in human breast cancer [24]. As in mice, shift
from DLX2 to DLX5 expression seems to be related to
progression toward an increasingly malignant phenotype.
However, DLX5 expression in human breast tumors is not
associated with expression of DLX6. This is not surprising:
also in human lymphomas upregulation of DLX5 occurs
without accompanying up-regulation of DLX6 [9].
We suggest that the alternative expression of DLX2 and
DLX5 might be considered as markers of better and
worse prognosis. It has to be noted that also in primary
lung tumors DLX5 expression is associated with poor
prognosis [25]. Both in our model system and in human
tumors, the expressions of DLX5 and DLX2 were
mutually exclusive, in agreement with other experimental
data demonstrating that these genes reciprocally downre-
gulate their expression in different territories [26,27].
The opposite expression pattern of DLX2 and DLX5 in
tumors are also consistent with previous observations,
showing that DLX2 is expressed at higher levels in tumor
cell lines which are more sensitive to apoptotic induction
by fenretinide, whereas DLX5 and DLX6 appear to segre-
gate in a distinct functional compartment [28]. The
involvement of ET1 signaling could be at the origin of
this switch in DLX gene expression. Indeed, ET-1 plays a
role in breast cancer progression: it is associated with
invading regions of tumors and is more common in
tumors with high histological grade and lymph node
invasion [29]. Furthermore, serum ET-1 is increased in
patients with lymph node metastases, compared to those
with no lymph node involvement. On these bases, ET-1
receptor antagonists have been used to prevent meta-
static spreading in animal tumor models [30,31]. How-
ever, clinical trials so far have failed to demonstrate a
therapeutical effect of this class of drugs in human solid
tumors [31,32]. Not surprisingly, ET-1 was not indepen-
dently predictive or relapse-free and overall survival in
breast cancer [33] and, in the dataset we used ET1 is
broadly present. Indeed, ET-1 induction could occur at
the site of metastases and not of primary tumors.
Conclusions
Herein we show that a DLX2-to-DLX5/6 switch in gene
expression occurs during metastasis formation by MDA-
MB-231 human breast carcinoma cells injected into
nude mice. This switch also occurs in vitro by treating
MDA-MB-231 cells with ET1. In breast carcinoma
patients, DLX2 expression is associated with increased
disease-free survival, while expression of DLX5 is pre-
sent in a small number of particularly aggressive cases.
Expressions of DLX2 and DLX5 a r em u t u a l l ye x c l u s i v e .
Our data suggest that DLX2 and DLX5 are involved in
human breast cancer progression, and that they might
serve as good or poor prognostic markers, respectively.
In particular DLX5 overexpression, together with conco-
mitant DLX2 downregulation, could identify a subset of
more aggressive cancers that would need a different
treatment and a more careful follow-up. We suggest
considering DLX2 and DLX5 as potential prognostic
markers, provided that our results are confirmed in a
different and broader cohort of patients.
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